Table 1 Clinical characteristics of the patient cohort
| Â | Number | % |
|---|---|---|
Age | ||
 Median | 54 |  |
 Range | 30–75 |  |
Tumor size | ||
 Median | 30 |  |
 Range | 13–120 |  |
T status | ||
 T1 | 8 | 9.6 |
 T2 | 62 | 74.7 |
 T3 | 7 | 8.4 |
 T4 | 6 | 7.2 |
N status | ||
 N0 | 40 | 48.2 |
 N1 | 32 | 38.6 |
 N2 | 7 | 8.4 |
 N3 | 4 | 4.8 |
Stage before NAC | ||
 Stage II | 68 | 81.9 |
 Stage III | 15 | 18.1 |
Type of surgery | ||
 Breast-conserving surgery | 38 | 45.8 |
 Mastectomy | 36 | 43.4 |
 Skin-sparing mastectomy | 8 | 9.6 |
 No operation | 1 | 1.2 |
Type of axial surgery | ||
 Sentinel lymph node biopsy | 15 | 18.1 |
 Axial dissection after sentinel lymph node biopsy | 4 | 4.8 |
 Axial dissection | 63 | 75.9 |
 No operation | 1 | 1.2 |
Subtype | ||
 Luminal A and luminal B | 54 | 65.1 |
 Luminal HER2 | 6 | 7.2 |
 HER2 positive | 10 | 12.0 |
 Triple negative | 13 | 15.7 |
Nuclear grade | ||
 I | 37 | 44.6 |
 II | 20 | 24.1 |
 III | 20 | 24.1 |
 Unknown | 6 | 7.2 |
FDG uptake | ||
 Negative | 0 | 0.0 |
 Positive | 83 | 100.0 |
Regimens of NAC | ||
 wPAC → FEC | 39 | 47.0 |
 DOC → FEC | 39 | 47.0 |
 FEC → DOC | 2 | 2.4 |
 FEC → DOC + H | 1 | 1.2 |
 FEC → PTX + Bev | 1 | 1.2 |
 wPAC | 1 | 1.2 |